Search jobs 28-Jun-2021 Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer s Disease in Greater China
DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Agreement
29.06.2021 / 01:03
The issuer is solely responsible for the content of this announcement.
Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer s Disease in Greater China
Halle (Saale)/Munich, Germany and Nanjing, China, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines and Simcere Pharmaceutical Group Ltd (HKEX: 2096) (Simcere) today announced that they have entered into a strategic regional licensin
DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance
vom 29.06.2021, 01:11 Uhr
Bild: pixabay.com
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance
29.06.2021 / 01:11
Vivoryon Therapeutics Provides Update on Financial Guidance
Halle (Saale) / Munich, Germany, June 29, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines, today announced an update on its financial guidance. According to current estimates, the Company expects the recently signed regional licensing agreement with Simcere Pharmaceutical Group Ltd. to have an impact on Vivoryon s previously communicated cash-reach of Q3 2022, which is anticipated to be extended for at least three quarters until Q2 2023. A detailed update on anticipated working capital requirements and resulting timelines will be giv
Investegate announcements from Immunicum AB, Immunicum Presents Data on Clinical Program DCP-001 at the European Hematology Association (EHA) 2021 Virtual Congress
Immunicum AB: Immunicum Announces Presentations at the European Hematology Association (EHA) 2021 Virtual Congress
Immunicum AB
. The presentations include interim immunological results from the Phase II ADVANCE II study, demonstrating DCP-001 s ability to induce immune responses to a broad range of tumor-associated antigens in acute myeloid leukemia (AML) patients, as well as preclinical results of enhanced efficacy when combining DCP-001 with established AML treatment regimens. From the interim clinical data published in the abstract today, we are excited to see that DCP-001 induces a range of detectable immune responses in AML patients participating in our ongoing ADVANCE II study, said